Angiocrine Bioscience Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Angiocrine Bioscience's estimated annual revenue is currently $5.3M per year.(i)
  • Angiocrine Bioscience's estimated revenue per employee is $155,000

Employee Data

  • Angiocrine Bioscience has 34 Employees.(i)
  • Angiocrine Bioscience grew their employee count by -17% last year.

Angiocrine Bioscience's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP, Clinical OperationsReveal Email/Phone
3
Chief Scientific OfficerReveal Email/Phone
4
Execuvite Director Preclinical DevelopmentReveal Email/Phone
5
Associate Director Clinical OperationsReveal Email/Phone
6
Senior Director, Technical OperationsReveal Email/Phone
7
Director, Clinical OperationsReveal Email/Phone
8
Senior Director, Project ManagementReveal Email/Phone
9
Director Quality, Cell TherapyReveal Email/Phone
10
Chief Operating OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Angiocrine Bioscience?

Angiocrine Bioscience is a private, clinical stage cell and gene therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions. Our team is developing a pipeline of proprietary engineered endothelial cell (E-CEL® ) therapies for treating multiple life-threatening hemato-oncologic and immunologic conditions, as well as, regenerating tissues and organs that have been injured or damaged by diseases.

keywords:N/A

N/A

Total Funding

34

Number of Employees

$5.3M

Revenue (est)

-17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.5M346%N/A
#2
$5.7M34-8%N/A
#3
$3.9M34N/AN/A
#4
$2.6M3431%$43M
#5
$3.6M34-41%$132.5M